Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CBIO
CBIO logo

CBIO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Crescent Biopharma Inc (CBIO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
16.700
1 Day change
-15.31%
52 Week Range
27.500
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CBIO is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has positive momentum and is trading above key moving averages, but there is no recent news catalyst, no meaningful institutional or insider buying, no strong proprietary buy signal, and the available analyst target is only slightly above the current price. Given the setup, it looks more like a momentum-trading name than a high-conviction long-term entry. My direct view: hold off on buying it now.

Technical Analysis

Technically, CBIO is in an uptrend. MACD histogram is positive and expanding, the moving averages are bullish with SMA_5 > SMA_20 > SMA_200, and price closed above the pivot at 20.014 and near first resistance at 21.928. RSI_6 at 68.18 shows the stock is approaching overbought conditions rather than offering a clean bargain entry. The trend is constructive, but the current price is close to resistance, which reduces near-term upside clarity.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment looks bullish based on the low put-call open interest ratio of 0.41, which suggests call-heavy positioning. However, option volume is 0, so there is no active confirmation from recent trading flow. Implied volatility is extremely high at 498.04, indicating the options market expects very large price swings, but not necessarily a favorable long-term entry for a beginner.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
5

Positive Catalysts

  • Bullish technical trend, positive MACD expansion, price above key moving averages, and options positioning tilted toward calls. The market is also showing some strength versus a flat/no-news backdrop.

Neutral/Negative Catalysts

  • No news in the last week, no strong AI Stock Picker or SwingMax signal, no recent congress trading activity, no notable insider accumulation, and hedge funds are neutral. The analyst target was cut from $25 to $22, which limits upside from current levels. The stock is also near resistance and RSI is elevated.

Financial Performance

No usable financial snapshot was provided, so the latest quarter fundamentals cannot be assessed. Because of that, there is no clear evidence here to support a long-term buy based on revenue or earnings growth trends, especially for a beginner investor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright lowered its price target to $22 from $25 on 2026-03-02 while keeping a Buy rating. That is still bullish, but it shows reduced analyst enthusiasm. Overall Wall Street pros appear mildly positive, but not strongly convinced at current levels.

Wall Street analysts forecast CBIO stock price to rise
6 Analyst Rating
Wall Street analysts forecast CBIO stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.720
sliders
Low
22
Averages
28.2
High
35
Current: 19.720
sliders
Low
22
Averages
28.2
High
35
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
AI Analysis
2026-06-01
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
AI Analysis
2026-06-01
New
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded Crescent Biopharma to Neutral from Buy without a price target, saying the ivonescimab copycat thesis is less compelling after Merck and Kelun's sacituzumab tirumotecan plus pembrolizumab regimen produced a stronger efficacy profile than ivonescimab in the key first line lung car comparison.
H.C. Wainwright
Buy
downgrade
$25 -> $22
2026-03-02
Reason
H.C. Wainwright
Price Target
$25 -> $22
2026-03-02
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Crescent Biopharma to $22 from $25 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CBIO
Unlock Now

People Also Watch